7/28/2026 – Immunocore was downgraded by Wall Street Zen from “buy” to “hold”. 7/20/2026 – Immunocore was upgraded by Wall Street Zen from “hold” to “buy”. 7/12/2026 – Immunocore was downgraded by Wall Street Zen from “buy” to “hold”. Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.